Haemostasis and Paediatrics

Reference ranges in children

Haemostatic Screening tests are commonly used in children for:

- Investigation of bleeding.
- Pre-operative assessment.
- Assessment of potential non accidental injuries.
- Analysis of asymptomatic children with positive family histories.

Pre-analytical variables can confound haemostatic screening tests in children as:

- Difficult sample collection often leads to sample activation.
- Small volume collections necessitate appropriate sized collection tubes.
- Polycythaemia in neonates frequently requires adjusted citrate volume tubes.
- Jaundice and lipemia may interfere with automated coagulometers that depend on optical density for clot determination.

Developmental haemostasis refers to age related changes in the haemostatic system. These changes:

- Must be viewed as physiological.
- Probably protect children from thrombosis.
- Are important for accurately defining normal from abnormal.

Stago Reagents		2.0	1 M H 1 M
PT (sec/INR)	Day 1	Day 3	1 Month - 1 Year
STA®-Néoplastine® Cl plus (sec)	15.6* (14.4-16.4)	14.9* (13.5-16.4)	13.1 (11.5-15.3)
- The Hoopidonino of pide (600)	n=21 (10F / 11M)	n=25 (13F / 12M)	n=35 (8F / 27M)
STA®-Néoplastine® Cl plus (INR)	1.26* (1.15-1.35)	1.20* (1.05-1.35)	1.00 (0.86-1.22)
()	n=21 (10F / 11M)	n=25 (13F / 12M)	n=35 (8F / 27M)
STA®-Néoplastine R® (sec)	14.5 (12.3-16.6)	13.9 (12.5-14.7)	13.4 (12.3-14.9)
PTT (sec)	n=10 (5F / 5M)	n=10 (5F / 5M)	n=20 (3F / 17M)
STA®-PTT Automate	38.7* (34.3-44.8)	36.3* (29.5-42.2)	39.3* (35.1-46.3)
	n=21 (10F / 11M)	n=25 (13F / 12M)	n=33 (3F / 30M)
STA®-C.K. Prest®	N/A	N/A	34.4* (31.1-36.6)
STA =0.K. Plest			n=20 (3F / 17M)
STA®-Cephascreen®	39.7* (34.9-47.4)	38.0 (31.2-44.0)	32.2 (29.1-35.5)
BRINOGEN (g/L)	n=10 (4F / 6M)	n=10 (4F / 6M)	n=28 (3F / 25M)
	2.80 (1.92-3.74)	3.30 (2.83-4.01)	2.42* (0.82-3.83)
STA®- Fibrinogen	n=22 (10F / 12M)	n=21 (10F / 11M)	n=34 (7F / 27M)
DAGULATION FACTORS (%)			
STA®- Deficient II	54* (41-69)	62* (50-73)	90* (62-103)
STA®- Delicieni ii	n=23 (13F / 10M)	n=22 (11F / 11M)	n=22 (7F / 15M)
STA®- Deficient V	81* (64-103)	122 (92-154)	113 (94-141)
	n=22 (13F / 9M)	n=22 (11F/11M)	n=20 (6F / 14M)
STA®- Deficient VII	70* (52-88)	86* (67-107)	128 (83-160)
	n=22 (12F / 10M)	n=22 (11F / 11M)	n=20 (6F / 14M)
STA®- Deficient VIII	182 (105-329)	159 (83-274)	94* (54-145)
	n=20 (9F / 11M)	n=25 (12F / 13M)	n=21 (6F / 15M)
STA®- Deficient IX	48* (35-56)	72* (44-97)	71* (43-121)
	n=24 (11F / 13M) 55* (46-67)	n=23 (11F / 12M) 60* (46-75)	n=21 (5F / 16M) 95* (77-122)
STA®- Deficient X	n=22 (12F / 10M)	n=22 (11F / 11M)	n=21 (6F / 15M)
	30* (7-41)	57* (24-79)	89* (62-125)
STA®- Deficient XI	n=20 (10F / 10M)	n=22 (11F / 11M)	n=22 (6F / 16M)
	58* (43-80)	53* (13-97)	79* (20-135)
STA®- Deficient XII	n=20 (9F / 11M)	n=21 (11F / 10M)	n=21 (7F / 14M)
DAGULATION INHIBITORS			
STA®-Stachrom® AT III (%)	76* (58-90)	74* (60-89)	109* (72-134)
	n=21 (9F / 12M)	n=22 (10F / 12M)	n=41 (8F / 33M)
STA®-Staclot® Protein C (%)	36* (24-44)	44* (28-54)	71* (31-112)
OTA Gladidi 1 Toldili 0 (70)	n=22 (9F / 13M)	n=21 (10F / 11M)	n=25 (5F / 20M)
STA®-Stachrom® Protein C (%)	32* (24-40)	33* (24-51)	77* (28-124)
	n=20 (9F / 11M)	n=22 (11F / 11M)	n=24 (4F / 20M)
STA®-Staclot® Protein S (%)	36* (28-47)	49* (33-67)	102* (29-162)
	n=22 (13F / 9M)	n=24 (11F / 13M)	n=41 (8F / 33M)
STA®-Liatest® Free Protein S (%)	40* (37-42)	47* (40-57)	98 (80-116)
	n=10 (5F / 5M) N/A	n=11 (5F / 6M) N/A	n=20 (10F / 10M)
Asserachrom® Free TFPI (µg/mL)	N/A N/A	N/A N/A	7.13* (5.63-8.44) n=13 (0F / 13M)
	N/A	N/A	77.49 (69.42-85.58)
Asserachrom® Total TFPI (µg/mL)	N/A	N/A	n=13 (0F / 13M)
BRIN RELATED MARKERS (µg/mL)	-		
STA®- Liatest® D-Di	1.47* (0.41-2.47)	1.34* (0.58-2.74)	0.22 (0.11-0.42)
STA - Liulesi - D-Di	n=20 (10F / 10M)	n=23 (12F / 11M)	n=20 (7F / 13M)
STA®- Liatest® FM	N/A	N/A	5.78 (2.46-11.96)
	N/A	N/A	n=19 (9F / 10M)
ROCOAGULANT PHOSPHOLIPIDS (sec)	41.4* (32.8-48.2)	40.8 (34.4-46.3)	31.6 (20.6-40.7)
	(5F / 5M)	(5F / 5M)	(10F / 10M)
AFI (%)	(0. 7 0m)	(5. 7 UM)	(10171011)
	30* (22-39)	30* (25-39)	68* (55-83)
STA®- Stachrom® TAFI	n=10 (5F / 5M)	n=7 (3F / 4M)	n=18 (3F / 15M)

Stago Reagents		
PT (sec/INR)	1 - 5 Years	6 - 10 Years
STA®-Néoplastine® Cl plus (sec)	13.3* (12.1-14.5)	13.4* (11.7-15.1)
Cirt Hoopiasiine or plas (666)	n=43 (23F / 20M)	n=53 (22F / 31M)
STA®-Néoplastine® CI plus (INR)	1.03* (0.92-1.14)	1.04* (0.87-1.20)
200 00000000000000000000000000000000000	n=43 (23F / 20M)	n=53 (22F / 31M)
STA®-Néoplastine R® (sec)	13.9 (13.0-14.8) n=20 (10F / 10M)	14.6 (14.0-15.4) n=20 (10F / 10M)
APTT (sec)	11=20 (101 / 1011)	11=25 (101 / 1011)
STA®-PTT Automate	37.7* (33.6-43.8)	37.3* (31.8-43.7)
	n=56 (26F / 30M)	n=71 (27F / 44M)
STA®-C.K. Prest®	32.3* (29.8-35.0)	32.9* (30.8-34.8)
	n=22 (11F / 11M)	n=22 (12F / 10M)
STA®-Cephascreen®	31.6 (28.6_35.8)	33.1 (29.8-35.3)
FIBRINOGEN (g/L)	n=30 (15F / 15M)	n=31 (16F / 15M)
	2.82* (1.62-4.01)	3.04 (1.99-4.09)
STA®- Fibrinogen	n=43 (23F / 20M)	n=52 (22F / 30M)
COAGULATION FACTORS (%)		
STA®- Deficient II	89* (70-109)	89* (67-110)
STAW- Delicient II	n=67 (26F / 41M)	n=64 (23F / 41M)
STA®- Deficient V	97* (67-127)	99* (56-141)
OTAG Ballatotti V	n=67 (26F / 41M)	n=64 (23F / 41M)
STA®- Deficient VII	111* (72-150)	113* (70-156)
OING BOILDION VII	n=66 (25F / 41M)	n=64 (23F / 41M)
STA®- Deficient VIII	110* (36-185)	117* (52-182)
	n=45 (26F / 19M) 85* (44-127)	n=52 (20F / 32M) 96* (48-145)
STA®- Deficient IX	n=44 (25F / 19M)	n=51 (19F / 32M)
	98* (72-125)	97* (68-125)
STA®- Deficient X	n=66 (25F / 41M)	n=49 (20F / 29M)
	113 (65-162)	113 (65-162)
STA®- Deficient XI	n=41 (24F / 17M)	n=50 (18F / 32M)
	85* (36-135)	81* (26-137)
STA®- Deficient XII	n=39 (20F / 19M)	n=45 (17F / 28M)
COAGULATION INHIBITORS		
STA®-Stachrom® AT III (%)	116* (101-131)	114* (95-134)
One diadinom at in (70)	n=49 (26F / 23M)	n=59 (25F / 34M)
STA®-Staclot® Protein C (%)	96* (65-127)	100 (71-129)
	n=42 (21F / 21M)	n=53 (21F / 32M)
STA®-Stachrom® Protein C (%)	94* (50-134)	94* (64-125)
	n=39 (16F / 23M)	n=50 (17F / 33M)
STA®-Staclot® Protein S (%)	101* (67-136) n=49 (26F / 23M)	109* (64-154) n=59 (25F / 34M)
	93 (63-120)	98 (83-123)
STA®-Liatest® Free Protein S (%)	n=20 (10F / 10M)	n=20 (10F / 10M)
	6.75 (5.06-9.05)	6.69* (4.29-9.31)
Asserachrom® Free TFPI (μg/mL)	n=21 (11F / 10M)	n=20 (9F / 11M)
	76.33 (61.27-89.80)	73.99* (59.13-88.02)
Asserachrom® Total TFPI (µg/mL)	n=21 (11F / 10M)	n=20 (9F / 11M)
FIBRIN RELATED MARKERS (µg/mL)		
STA®- Liatest® D-Di	0.25* (0.09-0.53)	0.26* (0.10-0.56)
- SIA - Lidiesi D-Di	n=40 (19F / 21M)	n=39 (12F / 27M)
STA®- Liatest® FM	3.87* (1.65-5.08)	3.64* (2.36-5.02)
PROCOAGULANT PHOSPHOLIPIDS (sec)	n=18 (9F / 9M)	n=20 (10F / 10M)
	27.7* (22.8-35.4)	26.1* (20.0-33.2)
STA®- Procoag® PPL	(10F / 10M)	(10F / 10M)
TAFI (%)	((, 1000)
	77* (67-90)	77* (66-93)
STA®- Stachrom® TAFI	n=19 (10F / 9M)	n=20 (10F / 10M)

Stago Reagents T (sec/INR)	11 - 16 Years	Adults
	13.8* (12.7-16.1)	13.0 (11.5-14.5)
STA®-Néoplastine® Cl plus (sec)	n=23 (7F / 16M)	n=51
STA®-Néoplastine® Cl plus (INR) STA®-Néoplastine R® (sec)	1.08* (0.97-1.30)	1.00 (0.80-1.20)
	n=23 (7F / 16M)	n=51 (43F / 8M)
	15.0 (14.0-16.0)	14.7 (12.8-17.4)
	n=20 (10F / 10M)	n=20 (17F / 3M)
PTT (sec) STA®-PTT Automate	39.5* (33.9-46.1)	33.2 (28.6-38.2)
	n=54 (12F / 42M)	n=42
STA®-C.K. Prest®	34.1* (29.4-40.4)	29.1 (25.7-31.5)
	n=39 (8F / 31M)	n=40
	33.8 (28.0-37.9)	33.6 (26.3-40.3)
STA®-Cephascreen®	n=31 (14F / 17M)	n=26 (20F / 6M)
Brinogen (g/L)		
STA®- Fibrinogen	3.15 (2.12-4.33)	3.1 (1.9-4.3)
	n=21 (7F / 14M)	n=55 (47F / 8M)
AGULATION FACTORS (%)	00* (01.107)	110 (70 100)
STA®- Deficient II	90* (61-107)	110 (78-138)
OTAG Bollototti II	n=23 (6F / 17M)	n=44
STA®- Deficient V	89* (67-141)	118 (78-152)
	n=20 (5F / 15M)	n=44
STA®- Deficient VII	118 (69-200)	129 (61-199)
	n=22 (6F / 16M)	n=44
STA®- Deficient VIII	120* (59-200)	160 (52-290)
	n=24 (6F / 18M)	n=44
STA®- Deficient IX	111* (64-216)	130 (59-254)
	n=25 (6F / 19M)	n=44
STA®- Deficient X	91* (53-122)	124 (96-171)
	n=24 (7F / 17M)	n=44
STA®- Deficient XI	111 (65-139)	112 (67-196)
	n=24 (5F / 19M)	n=44
STA®- Deficient XII	75* (14-117)	115 (35-207)
DAGULATION INHIBITORS	n=22 (7F / 15M)	n=44
	111* (96-126)	96 (66-124)
STA®-Stachrom® AT III (%)	n=26 (8F / 18M)	n=43
	94* (66-118)	104 (74-164)
STA®-Staclot® Protein C (%)	n=25 (8F / 17M)	n=42
	88* (59-112)	103 (54-166)
STA®-Stachrom® Protein C (%)	n=20 (6F / 14M)	n=44
OTA @ Oh., . I - 1/2 D	103* (65-140)	75 (54-103)
STA®-Staclot® Protein S (%)	n=27 (9F / 18M)	n=44
CTA® Lightest® Free Breaking Q (0/)	97 (76-127)	97 (74-120)
STA®-Liatest® Free Protein S (%)	n=20 (10F / 10M)	n=20 (10F / 10M)
Association Research Control	7.66* (5.15-8.74)	10.70 (6.12-12.34)
Asserachrom® Free TFPI (µg/mL)	n=15 (6F / 9M)	n=20
Accordobrom® Total TEDL (ug/ml)	74.09 (61.63-87.36)	87.49 (63.64-104.38)
Asserachrom® Total TFPI (µg/mL)	n=15 (6F / 9M)	n=20
BRIN RELATED MARKERS (µg/mL)	0.07* (0.10.20)	0.10 (2.22.2.12)
STA®- Liatest® D-Di	0.27* (0.16-0.39) n=21 (6F / 15M)	0.18 (0.05-0.42) n=32 (19F / 13M)
	1=21 (6r / 15M) 3.18* (1.06-5.65)	10.24 (2.43-25.71)
STA®- Liatest® FM	n=20 (10F / 10M)	n=20 (17F / 3M)
ROCOAGULANT PHOSPHOLIPIDS (sec)	11-20 (101 / 1011)	11-20 (171 / 514)
	27.6* (20.7-36.2)	36.4 (29.6-43.2)
STA®- Procoag® PPL	n=20 (10F / 10M)	n=20
FI (%)	(, 1000)	
	86* (65-106)	110 (72-143)
STA®- Stachrom® TAFI	n=20 (10F / 10M)	n=15 (13F / 2M)

Results of coagulation assays are system and reagent dependent. Age-related reference ranges must therefore be developed for each reagent/ coagulometer combination to facilitate accurate diagnosis of paediatric samples. Published data confirms that reference ranges generated using a specific reagent/ coagulometer combination cannot be applied to any other reagent/ coagulometer system.

The reference ranges were generated at Royal Children's Hospital, Melbourne Australia, (Prof Paul Monagle) from samples collected in 3.2% citrate and analysed using STA® analysers line and reagents as indicated.

This second edition includes new parameters recently discovered in the field of haemostasis. For each test/reagent the first row shows the mean and boundaries including 95% of the population.

The second row shows the number of individual samples and the ratio of males to females for each group.

Stago wishes to acknowledge Professor Paul Monagle and his Team from The Royal Chidren's Hospital, Melbourne, Australia, for their expertise and for establishing all the data reported in this document.

Data extracted from: Monagle P. et al. Thromb Haemost 2006; 95: 362-372.

Summerhayes R. et al. J of Thromb and Haemost, 2009, 7, Supp 2: P-WE-480. Summerhayes R. & al. J of Thromb and Haemost, 2007; 5, Supp 2: P-M-105. Summerhayes R. & al. J of Thromb and Haemost, 2007; 5, Supp 2: P-S-397.

 $^{^{}st}$ Denotes values that are significantly different from adult values (p<0.05).